DaVita begins operations in Brazil
DaVita inicia sua operações no Brasil
Intel ID : 230082
| Synopsis |
|
US-based DaVita (NYSE: DVA), global supplier of of kidney treatment, announced it will begin its operations in Brazil, as published by newspaper R7 on 30 September 2015, citing its CEO of international operations, Dennis Kogod DaVita also announced it plans to sign partnership agreements with the Brazilian government and health insurance companies, as well as expand integrated treatment options. DaVita is a company that focuses on exploration of hemodialysis centers.
(content in portuguese)
A norte- americana DaVita (NYSE: DVA), provedora mundial de tratamento renal, anunciou o inicio das suas operações no Brasil, segundo publicou o jornal R7 no dia 30 de setembro de 2015, citando o executivo Dennis Kogod, CEO de operações internacionais da DaVita. A empresa disse também que pretendem firmar parcerias com o governo brasileiro e seguradoras de saúde com a intenção de estabelecer e ampliar as opções de tratamento integrado. A DaVita, sediada nos Estados unidos, é uma empresa dedicada à exploração de centros de hemodiálise. |
| Intel ID | 230082 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - DaVita
(31 Dec 2012) |
Revenue: EUR 8.186,28m | |
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.03.02 Clinics & Primary Care 30 Healthcare / 30.03 Healthcare Facilities & Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.